Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Proteostasis Therapeutics strengthens leadership team

James DeTore, Geoffrey Gilmartin and Marija Zecevic join

- PMLiVE

Repositive appoints scientific lead

Manuel Corpas joins the genome software company

- PMLiVE

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

Kirsten Drejer steps down as Symphogen CEO

The biotech’s CFO Martin Olin succeeds her in the role

EFPIA director general Richard Bergström resigns

Will remain in the role until a successor has been selected

- PMLiVE

SO What Global launches patient engagement venture

New agency will focus on aiding pharma companies’ pursuit of patient-centricity

- PMLiVE

Medicines Discovery Catapult appoints CEO

Chris Molloy will take up the lead role in November this year

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links